tiprankstipranks
Company Announcements

ResMed Inc. CEO Reports Stock Transactions Under Rule 10b5-1 Plan

Story Highlights
  • ResMed Inc. is a healthcare company specializing in sleep and respiratory care solutions.
  • CEO Michael J. Farrell executed stock transactions under a Rule 10b5-1 plan, reflecting regulatory compliance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ResMed Inc. CEO Reports Stock Transactions Under Rule 10b5-1 Plan

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an update.

ResMed Inc. has reported a change in beneficial ownership as per a Form 4 filing with the SEC, indicating that CEO Michael J. Farrell executed transactions involving the acquisition and disposal of common stock under a pre-established Rule 10b5-1 plan. This transaction reflects the company’s ongoing adherence to regulatory compliance and may impact stakeholders’ perception of executive confidence in the company’s future performance.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of equipment related to sleep disorders and respiratory care. The company is known for its innovative solutions in sleep apnea treatment and other respiratory conditions, catering to a global market.

YTD Price Performance: -0.68%

Average Trading Volume: 1,062,192

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$55.39B

Find detailed analytics on RMD stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App